Antiproliferative and apoptosis inducing effects of indirubin-3'-monoxime in renal cell cancer cells

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6, 2011, Pages 815-820

  Perabo, Frank G E ^a,b   Landwehrs, Gregor ^a   Frössler, Christian ^a   Schmidt, Doris H ^a   Mueller, S C ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b NONE   (Netherlands)

Author keywords

Apoptosis; Indirubin 3' monoxime; Renal cell cancer; Survivin

Indexed keywords

INDIRUBIN; INDIRUBIN 3' MONOXIME; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN MCL 1; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 81055133599     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.10.005     Document Type: Article

References (35)

1. Coppin C., Le L., Porzsolt F., et al. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008, CD006017.
2. de Reijke T.M., Bellmunt J., van Poppel H., et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009, 45:765-773.
3. Rini B.I. Metastatic renal cell carcinoma: Many treatment options, one patient. J Clin Oncol 2009, 27:3225-3234.
4. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132.
5. Hoessel R., Leclerc S., Endicott J.A., et al. Indirubin, the active constituent of a Chinese antileukemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999, 1:60-67.
6. Shi J., Shen H.M. Critical role of Bid and Bax in indirubin-3'-monoxime-induced apoptosis in human cancer cells. Biochem Pharmacol 2008, 75:1729-1742.
7. Kim S.A., Kim Y.C., Kim S.W., et al. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res 2007, 13:253-259.
8. Perabo F.G., Frossler C., Landwehrs G., et al. Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. Anticancer Res 2006, 26:2129-2135.
9. Sethi G., Ahn K.S., Sandur S.K., et al. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-κB signaling pathway. J Biol Chem 2006, 281:23425-23435.
10. Moon M.J., Lee S.K., Lee J.W., et al. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg Med Chem 2006, 14:237-246.
11. Suzuki K., Adachi R., Hirayama A., et al. Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells. Br J Haematol 2005, 130:681-690.
12. Lee J.W., Moon M.J., Min H.Y., et al. Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells. Bioorg Med Chem Lett 2005, 15:3948-3952.
13. Nam S., Buettner R., Turkson J., et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 2005, 102:5998-6003.
14. Merz K.H., Schwahn S., Hippe F., et al. Novel indirubin derivatives, promising anti-tumor agents inhibiting cyclin-dependent kinases. Int J Clin Pharmacol Ther 2004, 42:656-658.
15. Eisenbrand G., Hippe F., Jakobs S., et al. Molecular mechanisms of indirubin and its derivatives: Novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 2004, 130:627-635.
16. Giard D.J., Aaronson S.A., Todaro G.J., et al. In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973, 51:1417-1423.
17. Fogh J., Fogh J.M., Orfeo T. One hundred twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977, 59:221-226.
18. Drevs J., Hofmann I., Hugenschmidt H., et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000, 60:4819-4824.
19. Lehner R., Lucia M.S., Jarboe E.A., et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 2002, 10:134-138.
20. Marko D., Schatzle S., Friedel A., et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 2001, 84:283-289.
21. Damiens E., Baratte B., Marie D., et al. Antimitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: Induction of endoreplication following prophase arrest. Oncogene 2001, 20:3786-3797.
22. [Clinical and experimental studies in the treatment of chronic granulocytic leukemia with indirubin (author's translation)]. Zhonghua Nei Ke Za Zhi 1979, 18:83-88.
23. Wu G.Y., Fang F.D. [Studies on the mechanism of indirubin action in the treatment of chronic granulocytic leukemia. II. Effects of indirubin on nucleic acid and protein synthesis in animal transplantable tumor cells and normal proliferating cells in vitro (author's translation)]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1980, 2:83-87.
24. Ji X.J., Zhang F.R., Lei J.L., Xu Y.T. [Studies on the antineoplastic action and toxicity of synthetic indirubin (author's translation)]. Yao Xue Xue Bao 1981, 16:146-148.
25. Wan J.H., You Y.C., Mi J.X., et al. [Effect of indirubin on hemopoietic cell production (author's translation)]. Zhongguo Yao Li Xue Bao 1981, 2:241-244.
26. Wu G.Y., Liu J.Z., Fang F.D., et al. Studies on the mechanism of indirubin action in the treatment of chronic granulocytic leukemia. V. Binding between indirubin and DNA and identification of the type of binding. Sci Sin [B] 1982, 25:1071-1079.
27. Wu K.M., Zhang M.Y., Fang Z., et al. [Potential antileukemic agents, synthesis of derivatives of indirubin, indigo, and isoindigotin]. Yao Xue Xue Bao 1985, 20:821-826.
28. Gan W.J., Yang T., Wen S., et al. Studies on the mechanism of indirubin action in the treatment of chronic myelocytic leukemia (CML). Chin Acad Med Sci Beijing 1985, 611-613.
29. Li F., Altieri D.C. The cancer anti-apoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999, 59:3143-3151.
30. Zamparese R., Pannone G., Santoro A., et al. Survivin expression in renal cell carcinoma. Cancer Invest 2008, 26:929-935.
31. Lechler P., Wu X., Bernhardt W., et al. The tumor gene survivin is highly expressed in adult renal tubular cells: Implications for a pathophysiological role in the kidney. Am J Pathol 2007, 171:1483-1498.
32. Krambeck A.E., Dong H., Thompson R.H., et al. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 2007, 13:1749-1756.
33. Byun S.S., Yeo W.G., Lee S.E., et al. Expression of survivin in renal cell carcinomas: Association with pathologic features and clinical outcome. Urology 2007, 69:34-37.
34. Sato A., Oya M., Ito K., et al. Survivin associates with cell proliferation in renal cancer cells: Regulation of survivin expression by insulin-like growth factor-1, interferon-γ and a novel NF- κB inhibitor. Int J Oncol 2006, 28:841-846.
35. Mahotka C., Krieg T., Krieg A., et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002, 100:30-36.